InterMune ex indicted in off-label probe

Think off-label marketing isn't a big deal? Tell that to InterMune's ex-CEO, who was indicted for trumping up the efficacy of his lung-disease product Actimmune and marketing it for an unapproved use. Prosecutors allege Dr. W. Scott Harkonen lied in a press release, saying that Actimmune extended the lives of patients with a fatal lung disease known as IPF. By touting Actimmune as an IPF remedy, they say, he was violating FDA rules against off-label marketing.

Harkonen's lawyer says there is data showing that Actimmune helps IPF patients. "By this indictment, the government is trying to criminalize an important potentially life-saving scientific debate," Brosnahan said. InterMune already paid $37 million to settle off-label marketing claims. Plus, the company said in a statement, Harkonen has left the building; he's now CEO of CoMentis, which says it's standing by its leader.

- read the San Jose Mercury News report

Suggested Articles

Alnylam is ready to follow on its Onpattro launch with an FDA nod for Givlaari. But the drug's safety profile is giving analysts reason to pause.

FDA nominee Stephen Hahn faced questions from Senators on Wednesday on topics including drug pricing, biosimilars, opioids and more.

BMS’ Opdivo-Yervoy combo been game-changing in late-stage melanoma. But when it comes to expanding the pair’s reach, the company has hit a roadblock.